×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLS – sellas life sciences group, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/14
07:36 pm
sls
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement [Yahoo! Finance]
Medium
Report
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement [Yahoo! Finance]
1/14
08:30 am
sls
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
Low
Report
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
1/6
08:27 am
sls
SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed? [Yahoo! Finance]
High
Report
SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed? [Yahoo! Finance]
12/29
09:02 am
sls
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) [Yahoo! Finance]
High
Report
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) [Yahoo! Finance]
12/29
08:35 am
sls
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
High
Report
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
12/25
11:47 am
sls
Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations [Yahoo! Finance]
Low
Report
Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations [Yahoo! Finance]
12/10
10:38 pm
sls
Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next [Yahoo! Finance]
Low
Report
Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next [Yahoo! Finance]
12/7
06:00 pm
sls
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
Low
Report
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
04:44 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Varian John
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Varian John
1/9
04:39 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: VAN NOSTRAND ROBERT L
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: VAN NOSTRAND ROBERT L
1/9
04:38 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: SCHEINBERG DAVID A
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: SCHEINBERG DAVID A
1/9
04:35 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: CICIC DRAGAN
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: CICIC DRAGAN
1/9
04:33 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Burns John Thomas
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Burns John Thomas
1/9
04:32 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Kalin Katherine Bach
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Kalin Katherine Bach
1/9
04:30 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Wasman Jane
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Wasman Jane
1/8
08:31 am
sls
Form 8-K SELLAS Life Sciences For: Jan 07
Medium
Report
Form 8-K SELLAS Life Sciences For: Jan 07
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/2
Form 8-K SELLAS Life Sciences For: Jul 01
37.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
TOP News Decliners
6/14
Form EFFECT SELLAS Life Sciences
-55.6%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: